Ikonisys Finalizes €500k Private Capital Increase

On February 27, 2025, Ikonisys SA announced the successful completion of a capital increase of €500,000 through a private placement. This transaction is part of the company's strategy to bolster its financial position and expand its shareholder base with specialized investors. The funds will be used to accelerate Ikonisys' global commercial expansion and aid its transformation into a hub for next-generation oncology diagnostics.

This capital increase was approved by the Board of Directors and executed without requiring the approval of the AMF. A total of 333,333 new shares were issued at €1.50 each, reflecting a 3% premium on the previous day's closing share price.

The capital injection strengthens the company's liquidity position, enabling it to meet financing needs for over 12 months. Following the capital increase, changes in shareholder percentages were noted, with the free float increasing to 28.81%.